2017 Virtual Symposium (Expired): CV Protection: Is It Achievable in Patients with T2DM?

According to 2014 data from the Centers for Disease Control and Prevention, 29.1 million individuals, or 9.3% of the US population, have type 2 diabetes mellitus (T2DM). Death from CV disease is 70% higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy, mostly due to premature CV death.

Evidence is accumulating that other factors besides impaired glucose metabolism play a role in the pathophysiology of T2DM and that a comprehensive approach against insulin resistance, obesity, hypertension, and dyslipidemia in addition to diet and exercise is required. In addition, because certain pharmacologic therapies were found to increase the risk of CV events, all new drugs introduced since 2008 have been mandated by the FDA to undergo CV safety outcome trials (CVOT) in high-risk T2DM patients. As a result, a growing body of evidence is accumulating on the ability of certain drugs to reduce CV mortality, overall mortality, and hospitalizations for worsening heart failure in high-risk patients with T2DM. This activity will review the prevalence of CV comorbidities in T2DM patients, present new data on the results of recent CVOTs, and discuss approaches to treatment that is targeted to maximizing outcomes in the T2DM patient with CVD.

CV Protection: Is It Achievable in Patients With T2DM?

Chairperson: Jay S. Skyler, MD

2017 Updated T2DM Treatment Guidelines: What's New?

Presenter: Wendy S. Lane, MD

CVOT Analysis for the Individualization of T2DM Treatment

Presenter: Robert H. Eckel, MD

Ongoing and Future CVOTs: How will they affect the future of T2DM Treatment?

Presenter: Benjamin M. Scirica, MD, MPH

Case Discussion

Chairperson: Jay S. Skyler, MD

Presenter: Wendy S. Lane, MDRobert H. Eckel, MDBenjamin M. Scirica, MD, MPH